These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 12369274

  • 1. Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations.
    Aymard N, Viala A, Clement MN, Jacquot M, Vacheron MN, Gauillard J, Caroli F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jun; 26(5):975-88. PubMed ID: 12369274
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan.
    Aymard N, Viala A, Baldacci C, Smagghe PO, Vacheron MN, Caroli F.
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Jan; 23(1):25-41. PubMed ID: 10368854
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.
    Watanabe K, Miura I, Kanno-Nozaki K, Horikoshi S, Mashiko H, Niwa S, Yabe H.
    Psychiatry Res; 2015 Dec 15; 230(2):419-23. PubMed ID: 26416588
    [Abstract] [Full Text] [Related]

  • 5. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
    Yoshimura R, Ueda N, Shinkai K, Nakamura J.
    Int Clin Psychopharmacol; 2003 Mar 15; 18(2):107-11. PubMed ID: 12598823
    [Abstract] [Full Text] [Related]

  • 6. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
    Yoshimura R, Shinkai K, Ueda N, Nakamura J.
    Pharmacopsychiatry; 2007 Jan 15; 40(1):9-13. PubMed ID: 17327954
    [Abstract] [Full Text] [Related]

  • 7. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E.
    Psychopharmacology (Berl); 2001 Jan 01; 153(2):238-43. PubMed ID: 11205425
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
    Oades RD, Klimke A, Henning U, Rao ML.
    Hum Psychopharmacol; 2002 Jan 01; 17(1):15-27. PubMed ID: 12404703
    [Abstract] [Full Text] [Related]

  • 10. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
    Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathé AA.
    J Clin Psychopharmacol; 2010 Oct 01; 30(5):496-503. PubMed ID: 20814316
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risperidone plasma levels, clinical response and side-effects.
    Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ.
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug 01; 255(4):261-8. PubMed ID: 15565299
    [Abstract] [Full Text] [Related]

  • 13. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M.
    Psychiatry Res; 2009 Jul 30; 168(2):110-8. PubMed ID: 19501918
    [Abstract] [Full Text] [Related]

  • 14. Risperidone in the treatment of psychotic depression.
    Goto M, Yoshimura R, Kakihara S, Shinkai K, Yamada Y, Kaji K, Ueda N, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun 30; 30(4):701-7. PubMed ID: 16580110
    [Abstract] [Full Text] [Related]

  • 15. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.
    Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB, Hong JS.
    J Neuroimmune Pharmacol; 2012 Sep 30; 7(3):656-64. PubMed ID: 22730040
    [Abstract] [Full Text] [Related]

  • 16. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H.
    Hum Psychopharmacol; 2005 Jun 30; 20(4):243-8. PubMed ID: 15830401
    [Abstract] [Full Text] [Related]

  • 17. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J.
    World J Biol Psychiatry; 2010 Mar 30; 11(2 Pt 2):256-61. PubMed ID: 20218790
    [Abstract] [Full Text] [Related]

  • 18. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine.
    Hatzimanolis J, Lykouras L, Markianos M, Oulis P.
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct 30; 22(7):1077-85. PubMed ID: 9829289
    [Abstract] [Full Text] [Related]

  • 19. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
    Yoshimura R, Nakamura J, Ueda N, Terao T.
    Int Clin Psychopharmacol; 2000 May 30; 15(3):175-80. PubMed ID: 10870876
    [Abstract] [Full Text] [Related]

  • 20. Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology.
    Markianos M, Botsis A, Arvanitis Y.
    Biol Psychiatry; 1992 Aug 01; 32(3):288-92. PubMed ID: 1384728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.